



(51) International Patent Classification:

C07D 491/107 (2006.01) A61P 35/00 (2006.01)
A61K 31/517 (2006.01) C07D 401/14 (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2024/054007

(22) International Filing Date:

31 October 2024 (31.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/546,727 31 October 2023 (31.10.2023) US
63/599,455 15 November 2023 (15.11.2023) US

(71) Applicant: **C4 THERAPEUTICS, INC.** [US/US]; 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US).

(72) Inventors: **JACKSON, Katrina L.**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **LIANG, Yanke**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **HANLEY, Ronan, Patrick**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **KREGER, Bridget**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US). **POLLOCK, Roy, Macfarlane**; c/o C4 Therapeutics, Inc., 490 Arsenal Way, Suite 120, Watertown, MA 02472 (US).


(74) Agent: **BELLOWS, Brent R.** et al.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOUNDS FOR THE DEGRADATION OF MUTANT BRAF

FIG. 85



(57) Abstract: The present invention provides compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions that can be administered to a host such as a human in need thereof for the treatment of a disorder, such as cancer, mediated by mutant BRAF. The compounds efficiently degrade Class I, II and III mutant BRAF proteins.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*